A total of 599 patients diagnosed with TB and HIV were enrolled. Participants were excluded if they were ⩽18 years-old (n=31) or if they were not ART-naïve (n=36). Among the 533 participants included in the analysis, the median age was 38 years (IQR 31-45 years) and 61% were female. Overall, 25% (135 out of 533) participants reported having ever smoked. Ever-smokers were older ( p=0.007) and a larger proportion of males (111 (51%) out of 216) than females (24 (8%) out of 317) reported any smoking ( p<0.001). Among ever-smokers, 6% (8 out of 135) reported current smoking, 25% (34 out of 135) were recent smokers, and 69% (93 out of 135) were former smokers. Among former smokers, 37% (34 out of 93) stopped smoking ⩾10 years ago. Duration of smoking differed by sex, with 33% of males and 79% of females smoking for <10 years. Compared with those who never smoked, ever-smokers were less likely to have finished secondary education ( p=0.036), more likely to experience food insecurity ( p=0.006), and more likely to report risky behaviours including heavy drinking ( p<0.001), sexual activity before 13 years of age ( p=0.039) and multiple sexual partners ( p<0.001 among females, p=0.745 among males). Employment status, underweight, functional status and TB disease location did not differ significantly between ever-smokers and never-smokers.
Baseline CD4 cell count was available in 522 (98%) participants. Median CD4 cell count was higher in current/recent smokers (266 cells·mm ; p=0.006). The same proportion (79%) of never-smokers and ever-smokers had a baseline CD4 cell count <350 cells·mm . Ever-smokers eligible for ART were 30% less likely to start ART during TB treatment (adjusted HR 0.70, 95% CI 0.54-0.90). Among those initiating ART, adherence to ART was similar among ever-and never-smokers (68% versus 77%; p=0.131).
Adverse TB treatment outcomes were experienced by 19% of participants: 11% (56 out of 533) were LTFU, 9% (46 out of 533) died during TB treatment and none experienced TB treatment failure. The proportion of individuals who experienced adverse TB treatment outcomes was higher in those who did not initiate ART (62 (37%) out of 166) compared with those who started ART (40 (11%) out of 367; p<0.001). Patients who were eligible for ART but failed to initiate ART were most likely to experience adverse TB treatment outcomes (52 (72%) out of 72). Ever-smokers were about twice as likely to experience adverse TB treatment outcomes compared with never-smokers (crude HR 2.15, 95% CI 1.45-3.20) (table 1). The association was significant after adjustment for covariates among all patients (adjusted HR 1.57, 95% CI 1.00-2.47) and people on ART (adjusted HR 2.21, 95% CI 1.16-4.22), but not among those who did not initiate ART during TB treatment (adjusted HR 1.15, 95% CI 0.46-2.88). When examining the type of adverse TB treatment outcome, LTFU was independently associated with smoking status (adjusted HR 2.40, 95% CI 1.13-5.11), but death was not (adjusted HR 0.87, 95% CI 0.38-1.98). ), ART initiation during TB treatment, extrapulmonary TB, completion of secondary education, employment, food insecurity (hungry in the past week), multiple sexual partners (excluded for the mortality analysis), sexual activity before age 13 years of age (excluded for the mortality analysis), and heavy alcohol consumption (World Health Organisation 2014 definition [6] ). ART: antiretroviral treatment; TB: tuberculosis; HR: hazard ratio; LTFU: lost to follow-up. When stratified by duration of smoking, smoking was independently associated with adverse TB treatment outcome among those reporting smoking for ⩾10 years (adjusted HR 2.39, 95% CI 1.36-4.22) but not among those smoking for <10 years (adjusted HR 1.28, 95% CI 0.67-2.44). When further stratifying by ART status during TB treatment, patients who had smoked for ⩾10 years and initiated ART during TB treatment were five times as likely to be LTFU (adjusted HR 5.11, 95% CI 0.96-27.06) and almost four times as likely to die (adjusted HR 3.81, 95% CI 0.99-14.58) compared with never-smokers who initiated ART.
Finally, those who reported recent or current smoking were nearly three times as likely to experience adverse TB treatment outcomes compared with those who had never smoked (adjusted HR 2.71, 95% CI 1.42-5.16).
Few studies have assessed smoking as a risk factor for adverse care outcomes in people living with TB and HIV. Regarding LTFU, individuals in Brazil [7] who smoked in the 6 months preceding TB treatment were twice as likely to be LTFU (adjusted OR 2.62, 95% CI 1.31-5.26). In Thailand [8] , current smoking was also associated with twice the odds of LTFU (adjusted OR 2.3, 95% CI 1.3-4.1). Regarding mortality, a study from Iran [9] reported no effect of smoking, but only included three participants who had never smoked. In Brazil [10] , current smokers hospitalised for TB, 71% of whom were HIV infected and were predominantly ART-naïve, were at increased risk of death (adjusted OR 2.14, 95% CI 1.07-4.28), but estimates were not stratified by HIV or ART status.
In summary, we observed that ever-smokers eligible for ART were 30% less likely to initiate ART during TB treatment, and ever-smokers on ART were twice as likely to experience adverse TB treatment outcomes. The effect of smoking was most pronounced among those on ART who were current/recent smokers or those who had smoked for ⩾10 years. ART was a strong effect modifier, with the absence of an effect of smoking on adverse TB treatment outcomes likely due to the strong effect of the absence of ART on death and LTFU in TB patients. While tobacco smoke has well-known hazardous effects, smokers also have a different psychosocial risk profile, which could contribute to the observed relationship between smoking and adverse TB treatment outcomes. Our estimates were, however, adjusted for many of these psychosocial factors.
In addition to preventing people from smoking, helping smokers to quit and providing ART, the outcome of people living with HIV who develop TB might be improved by increasing support for (former) smokers, such as intensified counselling on the importance of ART. 
